I was hoping for a name change....but one that came with a takeover and some cash back.
All those Directors have had months to dream up a future path, and this is it.
And since I can't fit the new name into the blog title, this will be the last post.
This company should become someone's MBA case study - how Australian scientists made one of the most important therapeutic discoveries of the 20th century and how Australian businessmen trashed it in the marketplace.
As for the future?. No mention of LANI, and I expect this name change is partly designed to bury it. I presume changing the name is intended to fool fund managers who sunk capital into Biota.
Vapendavir might succeed in trials, but I have serious doubts it will get past FDA at the clinical advisory stage, especially without a rapid diagnostic. Any side effect of note will also bury it (like plecoranil).
The RSV drug has better prospects but its still very very early in its development, and being pushed pretty fast.
And the genital wart drug has a pretty small market and they overpaid.
Thanks if you read and responded. Good luck if you're long Avirogen.
